Five-year potency preservation after iodine-125 prostate brachytherapy
International Journal of Clinical Oncology,  Clinical Article

Nishimura S, et al. – The authors aimed to evaluate long–term erectile function following prostate brachytherapy, based on patient characteristics and treatment factors. Patient age at implantation and pre–treatment erectile function are predictive factors for the development of erectile dysfunction following prostate brachytherapy.


  • Between 2003 and 2006, 665 men with localized prostate cancer were treated with 125I permanent seed implantation.
  • None was given adjuvant hormone therapy.
  • Erectile function was assessed before treatment, and at 6 months, 1, 2, 3, 4 and 5 years after implantation using the Mount Sinai Erectile Function Score (MSEFS) of 0–3 (0 = no erections, 1 = erections insufficient for intercourse, 2 = suboptimal erections but sufficient for intercourse, 3 = normal erectile function).
  • Potency was defined as score 2 or 3, and 382 men were potent before treatment.
  • Univariate and multivariate analyses were performed on the data from these 382 patients to identify variables associated with potency preservation.


  • In patients who were potent before treatment, the actuarial potency preservation rate fell to 46.2 % at 6 months after brachytherapy, and then slowly recovered reaching 52.0 % at 5 years after brachytherapy.
  • In multivariate logistic regression analysis, patient age (p = 0.04) and pre–treatment MSEFS (p < 0.001) were predictors of 5–year potency preservation.
  • Neoadjuvant hormone therapy affected potency preservation only at 6 months after brachytherapy.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Urology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Urology Articles

1 Who dies from prostate cancer? Prostate Cancer & Prostatic Diseases, October 17, 2014    Clinical Article

2 Metformin use and prostate cancer risk Full Text European Urology, November 19, 2014    Free full text    Clinical Article

3 Castration-resistant prostate cancer: AUA guideline amendment The Journal of Urology, November 21, 2014    Clinical Guideline

4 Clinical practice guidelines on prostate cancer: A critical appraisal The Journal of Urology, November 6, 2014    Clinical Article

5 Diethylstilboestrol (1 mg) in the management of castration-resistant prostate cancer Urologia Internationalis, October 21, 2014    Clinical Article

6 Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening The Journal of Urology, November 11, 2014    Clinical Article

7 Prosbiotate: A multicenter, prospective analysis of infectious complications after prostate biopsy The Journal of Urology, November 12, 2014    Clinical Article

8 Current clinical presentation and treatment of localized prostate cancer in the United States The Journal of Urology, November 18, 2014    Clinical Article

9 The use of metformin in patients with prostate cancer and the risk of death Cancer Epidemiology, Biomarkers & Prevention, September 22, 2014    Clinical Article

10 Calcium and phosphorus intake and prostate cancer risk: A 24-y follow-up study American Journal of Clinical Nutrition, November 26, 2014    Clinical Article

11 The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study International Journal of Clinical Practice, November 5, 2014    Evidence Based Medicine    Clinical Article

12 Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation The Journal of Urology, October 30, 2014    Clinical Article

13 Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: A systematic review and meta-analysis World Journal of Urology, November 25, 2014    Clinical Article

14 Efficacy of high-dose palliative radiotherapy for localised, castration-resistant prostate cancer Clinical Oncology, November 17, 2014    Clinical Article

15 Daily aspirin use and prostate cancer–specific mortality in a large cohort of men with nonmetastatic prostate cancer Journal of Clinical Oncology, October 24, 2014    Clinical Article

16 Stereotactic body radiation therapy for prostate cancer: Rational and reasonable Practical Radiation Oncology, November 13, 2014    Clinical Article

17 Magnetic resonance-invisible versus magnetic resonance–visible prostate cancer in active surveillance: A preliminary report on disease outcomes Urology, November 13, 2014

18 Concordance between biopsy and radical prostatectomy specimen gleason score in internal and external pathology facilities Anticancer Research, October 22, 2014    Clinical Article

19 Primary gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy Full Text European Urology, November 24, 2014    Free full text    Clinical Article

20 A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies Full Text European Urology, November 20, 2014    Free full text    Evidence Based Medicine

Indexed Journals in Urology: Urology, Journal of Urology, European Urology, The Prostatemore